Skip to main content

Table 3 Cancer characteristics of male BRCA mutation carriers with breast cancer

From: Male BRCA mutation carriers: clinical characteristics and cancer spectrum

ID BRCA Gene Mutation Age at diagnosis Size (cm) LN Stage TNM stage Grade ER
%
PR
%
HER-2 Surgery Chemo RT Status F/U (yrs)
4 2 c.100G > T 75 1.4 neg I T1N0M0 2 92 18 pos M Yes, Trastuzumab no Alive, NED 5.7
8 2 c.736del20 52 N.A N.A N.A N.A 3 97 87 Border-line M yes, TCH yes Alive 5.6
3 2 c.1813dupA 58 1.3 pos II T2N1M0 3 59 50 neg M yes, AC yes Expired 15.8
5 2 c.2808del4 67 1.7 pos III T1N3M0 3 100 89 pos M yes, ACTH yes Alive, NED 3.4
1 2 c.2808del4 68 1.6 pos II T2N1M0 3 90 40 neg M Yes, AC-T yes Alive, NED 7.0
7 2 c.5946del T 62 N.A pos II N.A 3 90 N.A N.A M Yes,CMF yes Alive, NED 21.0
9 2 c.5946delT 67 N.A N.A N.A N.A N.A N.A N.A N.A N.A N.A N.A N.A N.A
2 2 c.6676_6677delGA 62 2.5 pos II T2N1M0 2 100 37 pos M yes, TCHP no Alive, NED 1.8
6 2 c.6333_6337delGAGAA 68 6.0 pos III T4N2M0 3 97 29 neg M N.A N.A Expired 2.3
  1. LN lymph node status, RT radiation therapy, M mastectomy, AC-T Doxorubicin, Cyclophosphamide and Paclitaxel, TCHP Docetaxel, Carboplatin, Trastuzumab and Pertuzumab, AC Doxorubicin and Cyclophosphamide, ACTH Doxorubicin, Cyclophosphamide, Paclitaxel and Trastuzumab, CMF Cyclophosphamide, Methotrexate and Fluorouracil, TCH Docetaxel, Carboplatin and Trastuzumab, NED no evidence of disease, F/U follow-up, NA not available, neg negative, pos positive